Affordable Access

deepdyve-link
Publisher Website

Current Concepts in Treatment of Barrett's Esophagus With and Without Dysplasia.

Authors
  • Schlottmann, Francisco1, 2
  • Patti, Marco G3, 4
  • 1 Department of Surgery, University of North Carolina, Chapel Hill, NC, USA.
  • 2 Center for Esophageal Diseases and Swallowing, University of North Carolina, 4030 Burnett Womack Building, 101 Manning Drive, CB 7081, Chapel Hill, NC, 27599-7081, USA.
  • 3 Department of Surgery, University of North Carolina, Chapel Hill, NC, USA. [email protected]
  • 4 Center for Esophageal Diseases and Swallowing, University of North Carolina, 4030 Burnett Womack Building, 101 Manning Drive, CB 7081, Chapel Hill, NC, 27599-7081, USA. [email protected]
Type
Published Article
Journal
Journal of Gastrointestinal Surgery
Publisher
Springer-Verlag
Publication Date
Aug 01, 2017
Volume
21
Issue
8
Pages
1354–1360
Identifiers
DOI: 10.1007/s11605-017-3371-8
PMID: 28353175
Source
Medline
Keywords
License
Unknown

Abstract

Patients with BE without dysplasia should undergo endoscopic surveillance every 3-5 years. Endoscopic ablative therapy (RFA) is the preferred treatment modality for dysplastic BE. Patients with T1a adenocarcinoma should be treated with EMR followed by ablative therapy. Low-risk T1b tumors may be suitable for endoscopic resection.

Report this publication

Statistics

Seen <100 times